### 1 Background

2 The varicella zoster virus (VZV) causes varicella, also known as chickenpox, and herpes zoster (HZ), known 3 as shingles. Almost everyone in Norway will get infected with VZV during their lifetime (1) and will develop varicella 4 translating to the annual incidence being fairly close to the annual number of births which is approximately 60,000 5 (2, 3). Each year approximately 14,600 varicella-associated visits are registered in the Norwegian healthcare sector 6 (4). The initial infection is rarely fatal in Norway, with an estimated 0.06 deaths per 100,000 case (4). Following 7 the initial infection, the virus remains latent in the spinal ganglion and about one in four (5) persons will experience 8 a reactivation of the virus later in life (6, 7). This corresponds to about 12,000 annual cases of HZ in Norway (2). 9 Despite the high prevalence and substantial disease burden, the financial burden of varicella and HZ in Norway is 10 not well described. The Norwegian healthcare system is government funded, and the current healthcare 11 expenditure is NOK 62,186 (€ 6,840) per capita annually. The total healthcare budget in 2016 was NOK 326 billion 12 (€ 35.9 billion), which corresponds to 10.5 % of national gross domestic product (GDP). This percentage is among 13 the highest in the world and has in later years increased by approximately 2% each year (8). It is therefore 14 important to take measures to reduce and contain healthcare costs where possible.

15 Effective vaccines against varicella have been available since 1984 (9), but are currently not included in 16 the Norwegian immunisation program. In recent years new vaccines against HZ have been also developed. A live 17 attenuated vaccine (Zostavax<sup>®</sup>) by Merck Sharp & Dohme has been available since 2006, and has been shown to 18 reduce the probability of developing HZ by about 50% (10). Another new subunit vaccine (Shingrix®) by 19 GlaxoSmithKline was approved in the United States in October 2017 (11) and received marketing authorization in 20 the European Union in 2018 (12). Shingrix<sup>®</sup> is believed to be more effective than Zostavax<sup>®</sup> vaccine in preventing 21 HZ, and is now recommended by the US Advisory Committee on Immunization Practices (ACIP) as the preferred 22 vaccine against HZ (13).

23 Despite the availability of vaccines against varicella and HZ, few countries use those in routine 24 immunisation, partly due to the concerns related to exogenous boosting hypothesis raised by Hope-Simpson in 25 the 1960's. Hope-Simpson observed that periods with a low incidence of varicella were followed by an increased 26 incidence of HZ (6) and therefore hypothesised that reducing or removing the incidence of varicella from the 27 population through a vaccine will increase the incidence of HZ. It has been estimated previously (2) that universal 28 varicella immunisation in Norway will almost eliminate varicella, but will also increase the occurrence of HZ, with 29 an incidence being 2.6 times higher at the peak compared to the pre-vaccine level. However, given availability of 30 HZ vaccines, reviewing a need for varicella and HZ immunisation is highly relevant. Thus, it is also important to 31 document the costs incurred by the diseases on the healthcare system. The objective of this study was therefore 32 to explore the financial burden of varicella and HZ in the Norwegian healthcare system. 33

## 34 Materials and Methods

#### 35 <u>Study Design</u>

This was a retrospective analysis of the costs associated with treating patients with varicella and HZ in the Norwegian healthcare system. We analysed the costs from a healthcare perspective using national registrybased data from the primary healthcare system and hospitals. Our group have previously reported estimates of varicella-related primary care consultations and hospitalisations and mortality based on the same dataset (14).

- 40 <u>Data Sources</u>
- 41 We used de-identifiable administrative data from the Norwegian Health Economics Administration42 (HELFO) and the Norwegian Patient Registry (NPR) to estimate costs for primary and hospital care, respectively.

The HELFO database contains the reimbursement claims from both general practitioners (GP) and emergency primary care clinics for each individual patient visit. The claims include information about the out-ofpocket amount paid by the patient, the reimbursement amount, and the amount paid by social security. Norwegian primary healthcare is financed through a combination of patient co-payment, reimbursement, and capitation fees. The HELFO data do not include the latter but capitation fees are derived by multiplying physician reimbursement fees by a factor of two as per the national guidelines for health technology assessment (15, 16). The amount of patient co-payment is set for each primary care visit and for patients who reach the yearly upper
limit of co-payment (€ 230 per 2017), the social security covers all co-payments for the remainder of the year.

We used all reimbursement claims containing ICPC (international Classification of Primary Care) codes
A72 (varicella) and S70 (HZ) registered during 2008-2014. A unique patient identification number allowed us to
identify the number of visits for each individual patient.

6 From NPR we extracted individual detailed data for all patients who visited a hospital during 2008-2014 7 with varicella or HZ-related diagnoses as coded by the International Classification of Diseases version 10 (ICD-10): 8 B01.0-B01.9 and P35.8 codes for varicella and B02.0-B02.9 codes for HZ. We included patients having varicella and 9 HZ as their primary or secondary diagnosis and grouped them by treatment level (inpatient, outpatient and 10 ambulatory care). The dataset included a unique patient identifier, age, sex, dates of admission and discharge, 11 ICD-10 codes and the associated Diagnosis Related Group (DRG) weights. In Norway, costs per hospital visit is 12 estimated for each of these groups. Since the DRG system is built on classifying groups of patients that are clinically 13 meaningful and intended to be homogenous with regards to resource intensity, these are regarded as good 14 estimates of costs. Hence, the DRG system is used both in financing Norwegian hospitals and recommended for 15 Norwegian health economic evaluations (15). In practice, average costs per DRG is typically given as a weight, 16 which has to be multiplied by the present monetary value of a DRG-weight to give the average cost of the 17 treatment of a patient within the DRG (15). Both DRG weights and the corresponding monetary values are updated 18 every year.

# 20 Data Analysis

19

21All costs were calculated in 2017 Norwegian kroner (NOK) by adjusting values based on the index for the22household real disposable income (17), as recommended by the Norwegian Directorate of Health (16) and23converted into 2017 Euros (NOK 1 =  $\in$  0.11). Primary care costs were analysed by age and treatment level.

24 When calculating mean cost of hospital services, we used all individual hospital encounters with complete 25 DRG-weights. For patients with incomplete data, we imputed averages based on age, treatment level, and whether 26 the patient had varicella and/or HZ as the primary or secondary diagnosis. Ambulatory care data from prior to 27 2013 were incompletely reported, therefore costs of ambulatory care were derived using observations reported 28 during 2013-2014 for both varicella and HZ. In-hospital costs were incompletely reported during the first two 29 years; 2008-2009, we therefore only used data for the period 2010-2014. We calculated costs for different 30 varicella and HZ-specific diagnoses. As patients' diagnoses may change during treatment, all relevant costs for the 31 different diagnoses were included to estimate the total cost. Costs of treatment for patients with HIV/AIDS, 32 malignancies, organ transplants, and immunosuppressive conditions were calculated separately.

# 34 Results

33

# **35** Varicella

From 2008 to 2014, there were 100,096 varicella-related visits in primary healthcare in Norway made by 76,168 patients (mean of 1.3 visits per patient). The average total cost of varicella-related visits in primary care was NOK 10.8 million or € 1,188,000 per year, translating to a mean cost per primary healthcare visit of 992 NOK (€ 109). This estimate includes the reimbursement, patient co-payment, a share covered by the social security scheme, and assumed capitation cost. Among all primary care costs, costs of GP visits accounted for 66.3 % and costs of visits with emergency primary care clinics for 31.3 % (Table 1).

Visit type	Varicella as primary diagnosis			Varicella as secondary diagnosis		
	Mean cost	Std. dev.	No.	Mean cost	Std. dev.	No.
	(€)	(€)	obs.	(€)	(€)	obs.
GP	337 (37)	206 (23)	74,539	342 (38)	162 (18)	26
Emergency primary care clinic	506 (56)	326 (36)	20,844	457 (50)	217 (24)	2,914

Table 1 Costs in NOK	of varicella-related prima	ry care visits, Norway, 2008-2014.	(Euro f in narentheses)
TUDIE I. COSIS, III NOK,	oj vancena-relatea prima	y cure visits, ivorwuy, 2008-2014.	(Euro, t, in purentieses)

Unknown*	318 (35)	136 (15)	820	663 (73)	338 (37)	953
Total	373 (41)	237 (26)	96,203	507 (56)	252 (28)	3,893

GP=General practitioner

\*Data about whether the contact was emergency care or not was not available for 1.8%

1

During 2010- 2014, a total of 2,172 varicella-related visits were registered in Norwegian hospitals giving
an average annual cost of NOK 12.4 million (€1,364,000). Hospital costs differed considerably by treatment level,
with a wide variation in costs at the inpatient level (Table 2). Average costs per hospital visits for
immunocompromised patients were NOK 65,100 (€7,200) compared to NOK 26,000 (€2,900) for
immunocompetent patients (Table A1). Hence, although immunocompromised patients represented only about
7% of all patients with varicella or HZ-related diagnoses, this patients group represented 17% of the costs.

8

Table 2. Costs, in NOK, of varicella-related hospital visits by treatment level, Norway, 2010-2014 (Euro, €, in
parentheses)

Varicella	Mean cost (€)	Std. dev. (€)	Obs.*	% missing DRG-weight**
Primary diagnosis				
Inpatient	58,163 (6,398)	105,510 (11,606)	653	0 %
Outpatient	1,834 (202)	453 (60)	850	8 %
Ambulatory ***	4,105 (442)	1447 (159)	20	32 %
Estimated mean****	24,735 (2,721)	72,624 (7,989)	1,610	
Secondary diagnosis				
Inpatient	66,752 (7,343)	114,328 (12,576)	324	0 %
Outpatient	1,512 (166)	615 (68)	188	15 %
Ambulatory ***	4,089 (450)	1,222 (134)	12	11 %
Estimated mean****	39,196 (4,312)	92,529 (10,178)	562	
Estimated total mean****	28,477 (3,132)	78,475 (8,632)	2,172	

\* observations represent the number of complete observations with accompanying DRG-weights for the whole period.

\*\* % missing DRG-weights refers to all observations from 2010-2014.

\*\*\* ambulatory care costs were calculated using observations made in 2013 and 2014.

\*\*\*\* estimated mean number of observations is based on complete observations, percentage missing and the fact that ambulatory care costs are based on fewer years than inpatients and outpatient costs (see: \*, \*\* and \*\*\*)

9 Of the annual costs associated with hospital varicella patients, 65% or NOK 8 million (€ 880,000) represent
10 the cost of patients having varicella as the primary diagnosis. The average annual cost of varicella in primary and
11 hospital care was approximately NOK 23.2 million (€ 2,552,000). The majority of these costs occurred in the age
12 group 0-14 years, with a small increase around the age of 35 -39 years, which may be related to increased virus
13 circulation among children and parents (Figure 1).

14 Ninety four percent of patients with varicella-related diagnosis had no comorbidities registered. Patients 15 with complications such as encephalitis and pneumonia accounted for a substantial proportion of the costs (28% 16 and 26%, respectively) despite accounting only for 3.5% and 3.0%, respectively, of all varicella cases (appendix 17 table A2). From 2010 to 2014, eight patients were registered with congenital varicella, which is a very rare 18 condition that can lead to a continuing need for future healthcare and increased healthcare costs, which were not 19 captured in our data. (Table A2).

21 Herpes zoster

20

During 2008-2014, there were 183,567 visits in the primary healthcare by 78,266 patients with HZ-related
diagnoses (mean of 2.4 visits per patient). The total annual cost of these visits amounted to approximately NOK
15.9 million (€ 1,749,000) or on average NOK 1,422 (€ 156) per visit. GP visits accounted for 84 % of the total

- 1 primary care costs, while visits with emergency primary care clinics made up 16 % (Table 3). As HZ is not a common
- 2 disease among the younger age groups, most of the costs were among those aged 50 years and above (Figure 2)

Table 3.	Cost of herpes zoster-related	primary care visits b	y treatment facility,	Norway, 2008-2014 (Euro, €, in
parenthe	eses)			

		Herpes zos	ter as main di	s main diagnosis Herpes zoster as seco diagnosis		ıdary	
		Mean cost (€)	Std. dev. (€)	Obs.	Mean cost (€)	Std. dev. (€)	Obs.
GP		270 (30)	229 (25)	149,166	424 (47)	293 (32)	13,349
Emergency prima clinics	ry care	472 (52)	301 (33)	18,708	605 (67)	387 (43)	904
Unknown*		247 (27)	163 (18)	1,382	378 (42)	234 (26)	58
Total		292 (32)	238 (26)	169,256	435 (48)	300 (33)	14,311

GP=General practitioner

\*Data about whether the contact was emergency care or not was not available for 0.8%

1

Table 4. Costs of herpes zoster-related hospital visits by treatment level, Norway, 2010-2014 (Euro,  $\epsilon$ , in parentheses)

Herpes Zoster	Mean cost (€)	Std. dev. (€)	Obs.*	% missing DRG- weight**
Main diagnosis				
Inpatient	63,212 (6,953)	41,267 (4,539)	1,660	0 %
Outpatient	1,237 (136)	533 (59)	4,733	39 %
Ambulatory ***	4,724 (520)	8,430 (927)	97	73 %
Estimated mean****	11,854 (1,304)	28,628 (8,643)	9,892	
Secondary diagnosis				
Inpatient	68,782 (7,566)	96,060 (10,567)	1,549	0 %
Outpatient	1,996 (220)	2,840 (312)	835	44 %
Ambulatory ***	7,250 (798)	11,855 (1,304)	28	42 %
Estimated mean****	35,284 (3,881)	75,452 (8,300)	3,119	
Estimated total mean****	17,471 (1,992)	45,690 (5,026)	13,011	

\* Number of hospital visits with accompanying DRG-weights for the whole period.

\*\* % of hospital visits with missing DRG-weights.

\*\*\* ambulatory care has been calculated using hospital visits from 2013-2014.

\*\*\*\* estimated mean number of observations is based on complete observations, percentage missing and the fact that ambulatory care costs are based on fewer years than inpatients and outpatient costs (see: \*, \*\* and \*\*\*)


4


During 2010-2014, 13,011 hospital encounters with HZ-related diagnoses were registered. The average
annual cost was NOK 45.5 million (€ 5 million) (Table 4). Patients with HZ as primary diagnosis represented 76% of
all hospital visits related to zoster, which incurred an annual cost of approximately NOK 23.5 million (€ 2,585,000).
Ninety one percent of these patients scored zero on the Charlson comorbidity index, suggesting absence of any
severe comorbidity. No large differences in costs were observed by diagnosis as compared to hospitalised varicella
patients (Table A2).

<sup>2</sup> 3

Although patients with HZ as a secondary diagnosis accounted only for 24 % of all zoster-related hospital
visits, costs associated with these patients represented almost a half of the total hospital cost (NOK 22 million / €
2,420,000 annually). The combined healthcare cost of HZ in primary and hospital care was estimated at
approximately NOK 61.4 million (€ 6,754,000) per year (Figure 1), with the majority of costs incurring in hospital
care (74%) and in individuals aged above 50 years (82%) corresponding to the increase in the zoster incidence.

5 6 7





8 Total cost

9 We estimate that varicella and HZ-related visits are associated with costs of approximately NOK 85 million
10 (€ 9,350,000) in the healthcare system annually in Norway. The majority of the costs (54%) are associated with
11 hospitalised HZ patients, followed by HZ patients treated by primary care system (19%). Varicella-associated
12 hospital costs account for 14% of the total disease cost, while the remaining 13% occur in the primary healthcare
13 (Figure 1).

#### 14

## 15 Discussion

16 The aim of this study was to document the economic burden of varicella and HZ in Norway in order to 17 inform a policy decision about the use of varicella and HZ immunization in Norway. Both varicella and HZ generate 18 substantial healthcare costs with the majority of the costs being associated with zoster patients. This is important 19 considering that varicella vaccination may increase the incidence of HZ, which will consequently increase the 20 associated costs. However, as estimated by Marchetti et al. (2), it could be possible to contain the negative effects 21 of varicella immunisation by introducing a concomitant HZ vaccination. The impact of HZ immunization will 22 however depend on several factors such as timing of vaccine introduction, chosen vaccination strategy, achieved 23 coverage and duration of vaccine-induced protection. In addition, introduction of HZ immunisation may be the 24 first public vaccination program for adults in Norway, and development and implementation of such program may 25 incur additional costs that could exceed the benefits.

26 This is the first cost-of-illness study of varicella and HZ in Norway (18). It is difficult to compare our findings 27 directly with other industrialised countries due to differences in the cost of labour, medications, and healthcare 28 systems. Other Nordic countries are the most relevant comparators due to similarities in populations and 29 healthcare systems. Nielsen et al. (19) assessed costs of HZ in Sweden by distinguishing between patients with HZ 30 and post-herpetic neuralgia (PNH), which we were unable able to calculate. The authors reported an average cost 31 of a hospitalisation at around 32,000 (2013) SEK and around 50,000 (2013) SEK for PHN, which is lower than our 32 estimates for Norway. This difference could be partially explained by a lower average wage rate in Sweden. 33 However, the same study reported an average cost of a GP visit with HZ of 1,544 (2013) SEK, which is roughly three

times higher than our corresponding estimate. Another study from Denmark (20) reported a cost of a GP visit to be more in line with our findings. Depending on the pain level associated with HZ, the number of visits ranged from 1.5 to 2.7, while cost per visit ranged from DKK 198 ( $\in$  26) to DKK 367 ( $\in$  47) (DKK 1 =  $\in$  0,13). This study also reported an average cost of a hospital visit of DKK 8,694 ( $\in$  1,130), which is close to our estimates of hospital visit for patients with HZ as the primary diagnosis ( $\in$ 1,304).

6 In our study we used a retrospective approach, which is limited in its ability to distinguish costs associated 7 with the disease from costs that are not. This is predominantly a problem for estimating costs for hospitalized HZ 8 patients as they often have several comorbidities, which may lead to an overestimation of the true costs directly 9 linked to the disease. Even when using costs associated with patients who had varicella or HZ as the primary 10 diagnoses, we may still have included the costs of any other diagnoses they might have had. If we however 11 excluded patients having either disease as their secondary diagnoses, we risk excluding costs related to the VZV 12 and thus underestimating the true economic burden. Whether varicella or HZ is coded as the primary or secondary 13 diagnosis could be arbitrary, because of accidental coding errors or possibly deliberate miscoding due to the 14 hospitals funding arrangements, thus, it is possible that the costs in our study were underestimated. It is important 15 to note that our estimates represent costs associated with either varicella or HZ assigned diagnosis, hence not all 16 costs included are in fact caused by the VZV. While HZ becomes more severe with age, the increase in the costs 17 seen in older people in our study is also related to a general increase in the morbidity.

18 We performed our analysis from a healthcare system perspective that does not include costs borne by 19 the patient or society. Although this perspective does not provide a complete picture of all disease costs, it gives 20 a good overview of most important costs, and is also the preferred perspective in the new Norwegian guidelines 21 for pharmacoeconomic analyses (15). Our approach did not include all costs borne by the healthcare services. For 22 example, we have not included the costs of prescription and non-prescription medications purchased by the 23 patients because we did not have access to these data. Costs of medications administered at hospitals will be 24 however accounted for as these are part of the hospital budget and therefore included in the DRG. Lastly, because 25 we extrapolated costs for hospital visits with missing DRG-weights, our estimates of the total hospital costs may 26 be somewhat imprecise.

## 28 Conclusion

Our study demonstrates that both varicella and HZ cause a substantial financial burden on the Norwegian healthcare system. The majority of the healthcare costs are associated with HZ, particularly in individuals over 50 years of age, and with varicella in children under age 15 years. These findings contribute to the knowledge base aimed to support the national policy decision about the need for varicella and HZ immunization, however, a full health economic evaluation is required before an informed decision can be made.

34

1

#### 2 References

Rimseliene G, Vainio K, Gibory M, Salamanca BV, Flem E. Varicella-zoster virus susceptibility and primary 1. healthcare consultations in Norway. BMC Infect Dis. 2016;16:254.

Marchetti S, Guzzetta G, Flem E, Mirinaviciute G, Scalia Tomba G, Manfredi P. Modeling the impact of combined 2 vaccination programs against varicella and herpes zoster in Norway. Vaccine. 2018;36(8):1116-25.

Births: [Available 3 Statistics Norway Statistics Norway: 2018 from: https://www.ssb.no/en/befolkning/statistikker/fodte (accessed 17th December 2018).

3456789 Mirinaviciute G, Kristensen E, Nakstad B, Flem E, Varicella-related Primary Health-care Visits, Hospitalizations 4. 10 and Mortality in Norway, 2008-2014. Pediatr Infect Dis J. 2017:1032-8.

11 Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. 5. BMC Public Health. 2015;15:466.

Hope-Simpson RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. 6. Proceedings of the Royal Society of Medicine. 1965;58:9-20.

Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25. 7.

Statistics 8. Norway. Health accounts 2017 [updated 14/03/2017. Available from: https://www.ssb.no/en/nasjonalregnskap-og-konjunkturer/statistikker/helsesat.

Varicella and herpes zoster vaccines: WHO position paper, June 2014. Releve epidemiologique hebdomadaire. 9 2014;89(25):265-87.

10. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352.

US Food & Drug Administration. Biologics License Application Approval 2017 [Available from: 11. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm581750.pdf (Accessed 17th December 2018

 $\begin{array}{c} 12\\ 13\\ 15\\ 16\\ 17\\ 19\\ 20\\ 22\\ 23\\ 25\\ 26\\ 28\\ 29\\ 31\\ 23\\ 33\\ 35\\ 36\\ \end{array}$ European Medicines Agency. Shingrix: Euroean Public Assessment Report 2018 [Available from: 12.https://www.ema.europa.eu/medicines/human/EPAR/shingrix#authorisation-details-section (Accessed 17th December 2018).

Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers cdc.gov: Centers for Disease Control 13.and Prevention; 2017 [Available from: https://www.cdc.gov/vaccines/vpd/shingles/hcp/index.html (Accessed 17th December 2018).

14. Mirinaviciute G, Kristensen E, Nakstad B, Flem E. Varicella-related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014. Pediatr Infect Dis J. 2017;36(11):1032-8.

Norwegian Medicines Agency. Guidelines for the submission of documentation for single technology assessment 15 (STA) of pharmaceuticals https://legemiddelverket.no/Documents/English/Price%20and%20reimbursement/Application%20for%20reimbursement/G

uidelines%20151018.pdf: (accessed 17th December 2018); 2018 [

37 Norwegian Directorate of Health. [Socioeconomic analyses in the health care sector - a guideline] In Norwegian 16. 38 39 2012 [Available from: https://helsedirektoratet.no/retningslinjer/veileder-i-okonomisk-evaluering-av-helsetiltak (Accessed 17th December 2018).

40 41 42 Statistics Norway. Main economic indicators 2004-2019. Accounts and forecasts. Nasjonalt Regnskap og 17. konjunkturer2016 [Available from: https://www.ssb.no/en/nasjonalregnskap-og-konjunkturer/artikler-ogpublikasjoner/gradual-upswing-expected-in-2017?tabell=259661 (Accessed 17th December 2018).

43 Gater A, Uhart M, McCool R, Préaud E. The humanistic, economic and societal burden of Herpes Zoster in Europe: 18. 44 a critical review. BMC Public Health. 2015;15(1):193.

- 45 Nilsson J, Cassel T, Lindquist L. Burden of herpes zoster and post-herpetic neuralgia in Sweden. BMC Infect Dis. 19 46 2015;15:215.
- 47 Bilde L. Nielsen TT, Ronholt F, Kruse M. The cost-effectiveness of introducing a vaccine for the prevention of 2048 herpes zoster and post-herpetic neuralgia in elderly Danes. Nordic Journal of Health Economics. 2016;5(2):7-27.

49

50

#### 1

# 2 Appendix

Table A1. Cost, in NOK, per hospital visit by patient's immunocompetence status, Norway, 2010-2014 (Euro,  $\in$ , in parentheses)

Varicella		Mean cost (€)	Std. dev. (€)	Obs.
Immunocompromised	Main diagnosis	59,981 (6,598)	166,612 (18,327)	65
	Sec. diagnosis	69,519 (7,647)	127,892 (14,068)	76
Immunocompetent	Main diagnosis	23,322 (2,565)	65,601 (7,216)	1,540
	Sec. diagnosis	34,454 (3,790)	84,895 (9,338)	486

3

4

Table A2. Mean total cost for patients with varicella and herpes zoster-related diagnoses<sup>\*</sup> (Euro,  $\in$ , in parentheses)

		Diagnosis	Mean (€)	Std. dev. (€)	Obs.
	B01.0	Varicella meningitis	71,667 (7,883)	53,114 (5,843)	119
æ	B01.1	Varicella encephalitis, myelitis & encephalomyelitis	140,693 (15,476)	225,740 (24,672)	66
aricella	B01.2	Varicella pneumonia	134,088 (14,750)	272,634 (29,990)	58
'ario	B01.8	Varicella with other complications	41,475 (4,562)	65,620 (7,219)	363
>	B01.9	Varicella without complications	17,431 (1,917)	53,764 (5,914)	1,298
	P35.8	Congenital varicella	100,863 (11,095)	101,820 (11,200)	8
	B02.0	Zoster encephalitis	44,889 (4,938)	88,405 (9,725)	203
Ŀ	B02.1	Zoster meningitis	49,203 (5,412)	30,861 (3,395)	54
Herpes zoster	B02.2	Zoster with other nervous system involvements	52,184 (5,740)	64,495 (7,094)	683
es z	B02.3	Zoster ocular disease	14,571 (1,603)	44,223 (4,865)	1,799
erp	B02.7	Disseminated zoster	49,780 (5,476)	58,632 (6,450)	95
Ť	B02.8	Zoster with other complications	50,292 (5,532)	79,992 (8,799)	596
	B02.9	Zoster without complications	35,890 (3,890)	69,237 (7,616)	3,433

5 \*based on the total cost for all visits the patient made. Patients whose first visit was before 2010 were excluded.

6 Costs for missing DRG-weights are included.